Mark Harrison

Affiliate Scientist, MSc, PhD


  • Assistant Professor, Faculty of Pharmaceutical Sciences, University of British Columbia
  • Scientist, Centre for Health Evaluation & Outcome Sciences

Research Interests

  • Treatment Outcomes
  • Epidemiology

Dr. Mark Harrison is a health economist and epidemiologist and an Assistant Professor in Sustainable Health Care, at the University of British Columbia’s (UBC) Faculty of Pharmaceutical Sciences. He joined the UBC Faculty of Pharmaceutical Sciences and CORE team in August 2014. Prior to joining UBC, Mark held the position of Senior Research Fellow in Health Economics, Centre for Health Economics, at the University of Manchester in the UK. He has a first class honours degree in Business and Management Sciences from the University of Bradford, an MSc from the University of Edinburgh, and a PhD in Epidemiology from the University of Manchester.

Dr. Harrison’s main research interests have been in evaluating treatment outcomes in chronic diseases; he has published numerous works on the epidemiology, cost-effectiveness of treatments, and patient health related quality of life, of those with rheumatic diseases using administrative and routinely collected data. More recently, Mark has explored the presentation and role of risk and uncertainty in patient health care decision making, with case studies in rheumatology, to support improved shared decision-making. He has also contributed to improving health care systems and health care delivery in the UK, through his work addressing the question of whether better quality management of chronic conditions in community-based primary health care, through mechanisms like incentive schemes, reduces emergency hospital admissions.

Dr. Harrison will continue to focus on chronic diseases and multimorbidity and combine these themes to improve the efficiency of the health care system in delivering timely, high quality of care, consistent with informed patient preferences, to improve patient outcomes and contain costs.


1. M Harrison, K Milbers, T Mihic, AH Anis. Incentives in Rheumatology: the Potential Contribution of Physician Responses to Financial Incentives, Public Reporting, and Treatment Guidelines to Health Care Sustainability. Current Rheumatology Reports 2016 18(7), 1-8.

2. Kolhatkar A, Cheng L, Chan F, Harrison M, Law MR. The Impact of Medication Reviews by Community Pharmacists Journal of the American Pharmacists Association 2016. Accepted May 2016.

3. Meacock R, Sutton M, Kristensen S-R, Harrison MJ. Using survival analysis to improve estimates of life year gains in policy evaluations. Medical Decision Making 2016 DOI: 10.1177/0272989X16654444.

4. Harrison MJ, Marra CA, Bansback N. Preferences for ‘new’ treatments diminish in the face of ambiguity. Health Economics 2016 DOI: 10.1002/hec.3353

5. Penton H, Hiligsmann M, Harrison M, Reginster JY, Boonen A, Bansback N. Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment. Osteoporosis International 2016 1-11.

6. Bansback N, Harrison M, Whitehurst DGT, Sadatsafavi M, Stiggelbout A. Attitude to health risk in the Canadian Population: evidence from a nationwide cross-sectional survey. CMAJ Open 21064 (2), E284.

7. Bansback N, Harrison M, Marra C. Does introducing imprecision around probabilities for benefit and harm influence the way people value treatments? Medical Decision Making 2016 36 (4), 490-502.

8. Harrison M, Marra C, Shojania K, Bansback N. Societal preferences for rheumatoid arthritis treatments.  Evidence from a discrete choice experiment.    May 2015.  10.1093/rheumatology/kev11F

9. Bansback N, Trenaman L, Harrison M. How important is mode of administration in treatments for rheumatic diseases and related conditions?  Current Rheumatology Reports. Current Rheumatology Reports 2015 17(6), 1-13.

10. Frew EJ, Harrison M, Rossello Roig M, Martin TPC. Providing an extended use of an ontological-specific outcome instrument to derive cost-effectiveness estimates of treatment.  Clinical Otolaryngology 2015. doi: 10.1111/coa.12424. [Epub ahead of print]  PMID: 25816901

11. Nikolova S, Harrison M, Sutton M. The impact of waiting time on health gains from surgery:  Evidence from a national patient reported outcomes dataset.  Health Economics 2015. DOI: 10.1002/hec.319.

12. Harrison M, Birch S, Eden M, Ramsden S, Farragher T, Payne K, Hall G. Black GC. Variation in healthcare services for specialist genetic testing and implications for planning genetic services:  the example of inherited retinal dystrophy in the English NHS.  J Community Genet. 2015 6(2), 157-165.  PMID: 25567483

13. Meacock R, Harrison M, McElhone K, Abbott J, Haque S. Bruce I, Teh LS. Mapping the disease-specific LupusQoL to the SF-6D.  Qual Life Res.  2014 Dec 16.  [Epub ahead of print].  PMID: 25510215

14. Harrison MJ, Dusheiko M, Sutton M, Gravelle H, Doran T, Roland M. Effect of a national primary care pay for performance scheme on emergency hospital admissions for ambulatory care sensitive conditions:  controlled longitudinal study.  British Medical Journal.  2014 Nov 11;349:g6423.  doi: 10.1136/bmj.g6423.  PMID: 25389120

15. Gavan S, Harrison M, Iglesias C, Barton A, Manca A, Payne K. Economics of stratified medicine in rheumatoid arthritis.  Current Rheumatology Reports.  2014 Dec;16(12):468. doi: 10.1007/s11926-014-0468-x.  PMID: 25366935

16. Heather E, Payne K, Harrison M, Symmons D. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis:  A systematic review of economic decision analytic models.    2014; 32(2):109-34.  PMID: 24338344

17. Harrison MJ, Rigby D, Vass C, Flynn T, Louviere J, Payne K. Risk as an attribute in discrete choice experiments:  A systematic review of the literature.    2014; 7(2):151-70.

18. Bujkiewicz S, Thompson JR, Sutton AJ, Cooper NJ, Harrison MJ, Symmons DPM, Abrams KR. Use of Bayesian multivariate meta-analysis to estimate the HAQ for mapping onto the EQ-5D questionnaire in rheumatoid arthritis.  Value Health.  2014; 17(1):109-15.  PMID: 24438724

19. Bujkiewicz S, Thompson J, Sutton A, Cooper N, Harrison MJ, Symmons D, Abrams KR. Multivariate meta-analysis of mixed outcomes:  A Bayesian approach.  Stat Med.  2013; 32(22):3926-43.

20. Meacock R, Dale N, Harrison MJ. The humanistic and economic burden of systemic lupus erythematosus (SLE):  A systematic review.    2013; 31(1):49-61.  PMID: 23329592

21. Harrison M, Ahmad Y, Haque S, Dale N, Teh L, Snowden N, Ho P, Gorodkin R, Bruce I. Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus.  Journal of Rheumatology.  2012; 39(4):735-42.

22. Harrison M, Reeves D, Harkness E, Valderas J, Kennedy A, Rogers A, Hann M, Bower P. A secondary analysis of the moderating effects of depression and multimorbidity on the effectiveness of a chronic disease self-management programme.  Patient Education and Counseling.  2012; 87(1):67-83.  PMID: 21767927

23. Harrison M, Fullwood C, Bower P, Kennedy A, Rogers A, Reeves D. Exploring the mechanisms of change in the chronic disease self-management programme:  Secondary analysis of data from a randomized controlled trial.  Patient Education and Counseling.  2011; 85(2):e39-e47.

24. Kirwan J, Boonen A, Harrison M, Hewlett S, Wells G, Singh J, Furst D, Dworkin R. OMERACT 10 Patient Perspective Virtual Campus:  Valuing Health; Measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health.  Journal of Rheumatology.  2011; 38(8):1728-34.  PMID: 21807793

25. Harrison M, Bansback N, Marra C, Drummond M, Tugwell P, Boonen A. Valuing health for clinical and economic decisions:  Directions relevant for rheumatologists.  Journal of Rheumatology.  2011; 38(8):1770-5.  PMID: 21807800

26. Foster H, Harrison M, Pain C, Symmons D, Baildam E. Delivery of paediatric rheumatology care in the UK – The projected shortfall.  Clinical Rheumatology.  2011; 30(5):679-83.

27. Camacho E, Harrison M, Farragher T, Lunt M, Bunn D, Verstappen S, Symmons D. Parity, time since last live birth and long-term functional outcomes:  A study of women participating in the Norfold Arthritis Register.  Annals of the Rheumatic Diseases.  2011; 70(4):642-5.

28. Harrison MJ, Lee S, Deighton C, Symmons DPM. UK Rheumatology Consultant Workforce Provision 2007-9:  Results from the BSR/Arthritis Research UK Consultant Workforce Register.  Clinical Medicine.   2011; 11(2):119-24.

29. Barta Z, Harrison M, Wangrangsimakul T, Shelmerdine J, The L, Pattrick M, Edlin H, Dale N, Ahmad Y, Bruce I. Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus.     2010; 19(3):231-8.

30. Harrison M, Lunt M, Verstappen S, Watson K, Bansback N, Symmons D. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.  Health and Quality of Life Outcomes.  2010; 11(8):21.

31. Harrison M, Boonen A, Tugwell P, Symmons D. Same question, different answers:  A comparison of global health assessments using visual analogue scales.  Quality of Life Research.  2009 Dec; 18(10):1285-92.

32. Harrison M, Davies L, Bansback N, McCoy M, Verstappen S, Watson K, Symmons D. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis.  Quality of Life Research.  2009; 18(9):1195-205.

33. Harrison M, Farragher T, Clarke A, Manning S, Bunn D, Symmons D. Association of functional outcome with both personal- and area-level socioeconomic inequalities in patients with inflammatory polyarthritis.  Arthritis and Rheumatology.  2009; 61(10):1297-304.

34. Harrison MJ, Davies LM, Bansback NJ, McCoy MJ, Farragher TM, Verstappen SS, Hassell A, Symmons D. Why do patients with inflammatory arthritis often score states “worse than death” on the EQ-5D?  An investigation of the EQ-5D classification system.  Value in Health.  2009; 12(6):1026-34.

35. Boonen A, Maetzel A, Drumond M, Suarez-Almazor M, Harrison M, Welch V, Tugwell P. The OMERACT Initiative.  Towards a reference approach to derive QALY for economic evaluations in rheumatology.  Journal of Rheumatology.  2009; 36(9):2045-9.

36. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DPM. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy:  Results from the British Society for Rheumatology Biologics Register.  Annals of the Rheumatic Diseases.  2009; 68(2):209-215.

37. Harrison MJ, Deighton C, Symmons D. An update on the UK Rheumatology Consultant Workforce Provision:  The BSR/ARC Workforce Register 2005-2007:  Assessing the impact of recent changes in NHS provision.  Rheumatology (Oxford).  2008; 47(7):1065-9.

38. Bansback N, Harrison MJ, Brazier J, Davies L, Kopec J, Marra C, Symmons D, Anis A. Health state utility values:  A description of their development and application for rheumatic diseases.  Arthritis and Rheumatology.  2008; 59(7):1018-26.

39. Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons D. The validity and responsiveness of generic utility measures in rheumatoid arthritis:  A review.  Journal of Rheumatology.  2008; 35(4):592-602.

40. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D. Modelling the cost effectiveness of TNF-α Antagonists in the management of rheumatoid arthritis:  Results from the British Society for Rheumatology Biologics Registry.  Rhematology (Oxford).  2007; 46(8):1345-1354.

41. Harrison MJ, Hassell A, Dawes P, Scott D, Knight S, Davis M, Mulherin D, Symmons D. The overall status in rheumatoid arthritis (OSRA) measure – further evidence to support its use in clinical practice.  Rheumatology (Oxford).  2007; 46(5):849-55.

42. Harrison MJ, Morley KD, Symmons D. Developments in rheumatology consultant manpower provision:  the VSR/ARC Workforce Register 2003-5.  Rheumatology (Oxford).  2006; 45(11):1416-21.

43. Symmons D, Tricker K, Harrison MJ, Roberts C, Davis M, Dawes P, Hassell A, Knight S. Mulherin D, Scott D. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatid drugs – results of the British Rheumatoid Outcome Study Group Randomized Controlled Trial.  Rheumatology (Oxford).  2006; 45(5):558-65.

44. Harrison MJ, O’Hare A, Campbell H, Adamson A, McNeillage J. Prevalence of autistic spectrum disorders in Lothian, Scotland:  An estimate using the “capture-recapture” technique.  Archives of Disease in Childhood.  2006; 91(1):16-9.

45. Harrison MJ, Tricker KJ, Davies L, Hassell A, Dawes P, Scott DL. Knight S, Davis M, Mulherin D, Symmons DPM. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis.  The Journal of Rheumatology.  2005; 32(12):2330-2336.

Share This